What Instillagel Treats: Main Uses and Benefits

Instillagel is generally used to provide short-term symptomatic assistance and supportive management in clinical settings where heightened localized discomfort is anticipated. The application is relevant when supportive symptom management is appropriate. The application is used across domains where additional symptomatic support is needed in the context of specific medical procedures, such as catheterization, cystoscopy, and urethral or rectal endoscopy.

---

Acute Symptomatic Relief in Procedures (Urology/Rectum)

This domain covers the application of the gel to help address symptoms related to physical discomfort that arise during necessary medical interventions. It is relevant in clinical settings marked by increased patient distress. The application is commonly used to help with symptomatic assistance and offers symptomatic relief that helps patients cope more steadily with difficult episodes.

“The application is relevant in contexts marked by increased discomfort or tension.”

Supportive Management of Localized Discomfort

The gel is applied across domains where additional symptomatic support is needed, relevant in conditions characterized by periods of heightened symptoms related to sensitive mucosal surfaces. It is commonly used in scenarios where localized discomfort may intensify temporarily, such as during the exchange of fistula catheters or easing localized distress. This use supports general well-being and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supports in managing Acute Procedural Discomfort

Regulatory References

1. HPRA Summary of Product Characteristics

Who Can and Cannot Use Instillagel?

Eligibility for Instillagel use is strictly defined by regulatory documents, focusing on patient sensitivities and the risk of systemic absorption of the active ingredient, Lidocaine Hydrochloride.

---

Absolute Contraindications (Must Not Use)

Instillagel is contraindicated and must not be used in the following populations:

• Hypersensitivity: Patients with known allergy to Lidocaine, Chlorhexidine, other amide-type local anaesthetics, or any excipients, including parabens.
• Age: Children below the age of 2 years.
• Cardiac Function: Individuals with significant disorders of the heart's conduction system.

---

Restricted and Conditional Use

Use requires special caution or a reduced dose in populations with conditions that increase the risk of systemic toxicity:

• Organ Function: Patients with Impaired Hepatic Function (liver) or Impaired Renal Function (kidney).
• Neurological Risk: Patients with epilepsy or a predisposition to convulsions.
• Patient Status: Debilitated, elderly, or acutely ill patients often require reduced doses.
• Application Site: Use on damaged, ulcerous, or bleeding mucous membranes requires caution due to increased absorption.

---

Pregnancy and Lactation

Status	Regulatory Statement
Pregnancy	Restricted during the first trimester; use only if absolutely necessary.
Lactation	Breastfeeding should be suspended for up to 12 hours after administration.

The official interaction profile for Instillagel is structured around the potential for systemic absorption of the active ingredient, Lidocaine Hydrochloride, and its subsequent clearance. Regulatory sources detail two primary types of interactions.

The first category involves pharmacokinetic interactions that modify drug exposure. Certain medicines are documented to inhibit the hepatic clearance of Lidocaine, leading to increased plasma concentrations. Examples of substances that may cause this reduction in clearance include the anti-ulcer medicine Cimetidine and specific beta-blockers like Propranolol. This increase in systemic exposure elevates the potential for toxicity.

The second category is pharmacodynamic synergism, where toxic effects become additive. Co-administration of Instillagel with other local anaesthetics is officially stated to result in additive toxic effects. Similar caution applies to the co-use of Class I antiarrhythmic drugs (e.g., Mexiletine), which carry the risk of additive effects on the heart. A specific risk note highlights that co-administration with other oxidizing agents increases the documented risk of methemoglobinemia.

Finally, the regulatory profile includes specific notes that impaired cardiac or hepatic function elevates the clinical significance of these drug interactions, as these conditions reduce the patient's capacity to clear Lidocaine or compensate for its systemic effects.

Localized Blockade of Nerve Signal Transmission

Instillagel exerts a dual, parallel mechanism of action via its two active components. The anesthetic component, Lidocaine, primarily targets voltage-gated sodium channels ( Na v) found on the membranes of peripheral sensory neurons. By functioning as a non-competitive ion flux inhibitor, Lidocaine enters and physically blocks the central pore of the channel. This action prevents the influx of sodium ions necessary to generate the action potential, resulting in the inhibition of nerve impulse conduction along the axon. This mechanism creates a state of functional sensory nerve silence at the site of application.

Non-Specific Microbial Cell Disruption

The antiseptic component, Chlorhexidine, acts by binding to the negatively charged components of the microbial cell membrane. This binding, facilitated by its cationic charge, rapidly compromises the structural integrity of the cell wall and membrane. This membrane disruption causes increased permeability and leakage of essential cellular contents, ultimately leading to the coagulation and precipitation of intracellular macromolecules. This cascade results in the rapid loss of viability and function of microbial cells, providing surface antisepsis.

Instillagel’s administration is governed by product information, which details the required volumes, timing, and procedural technique for its use as a topical instillation. The product is supplied in single-use syringes and is intended for intermittent application only.

---

Administration Scope

Category	Instruction
Route of Administration	Topical instillation into body orifices, including urethral (male/female), vaginal, rectal, and oropharyngeal/endoscopy sites.
Dosing Schedule	Catheterization/Urethral: Instil 6 ml or 11 ml. Cystoscopy/Endoscopy (Male): Instil 11 ml, with an optional additional 6 ml or 11 ml. The maximum dose is limited to 4 syringes in a 24-hour period.
Preparation Requirements	Requires prior completion of the usual cleaning of the glans and external orifice before instillation.
Age-Group Rules	Children (2–12 years): Maximum dose must not exceed 2.9 mg of lidocaine hydrochloride per kg of body weight. Older/Debilitated Patients: Should be administered reduced doses.
Special Procedural Conditions	The gel must be instilled slowly. A mandatory 5 to 10 minute waiting period is observed before the procedure commences.

---

Instruction Classifications

Category	Classification
Administration Method Type	Topical Instillation (Local)
Frequency Pattern	As-needed (PRN), tied strictly to a single procedural event; Intermittent use only.

---

Connection to the Overall Use Protocol

Instructions establish that the medicine is used via slow, topical instillation in conjunction with a procedure, which defines its intermittent, as-needed frequency pattern. These guidelines standardize the volume (6 ml or 11 ml) based on the procedure, introduce necessary waiting periods, and impose maximum dose limits per 24 hours and weight-based limits for children, all of which govern the correct administration across different patient groups and clinical scenarios.

Research evidence / Overview of Studies for Instillagel

Evidence for Use in Urethral Procedures (Catheterization and Cystoscopy)

Research exploring Instillagel has primarily focused on its use in procedures involving the urethra, such as catheterization and cystoscopy. The main evidence was evaluated in Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews and Meta-analyses. These studies compared the lidocaine-based gel against a non-active lubricant or placebo, regarding the study of pain perception and procedural ease when the gel was used. Studies reported measurements of pain scores during device insertion in certain adult male cohorts, and data showed patterns related to reduced perceived discomfort compared to control groups. However, findings were less consistent when the research examined adult female patients. The outcomes observed were short-term, providing assessments only during the immediate post-procedural period. Regulatory documentation describes the medicinal use as established in this domain. Comparative evidence is lacking to show the specific, independent contribution of the antiseptic component to infection prevention.

Evidence for Use in Rectal and Other Internal Examinations

The evidence base for the gel's application in non-urological settings, such as rectal examinations, is supported largely by Regulatory Documentation citing established clinical practice. Small-scale Randomized Controlled Trials explored outcomes related to physical discomfort and procedural ease during internal examinations. Research explored whether the use of the gel was associated with certain patterns of symptomatic support. Data are still emerging, and the evidence is limited to a modest number of dedicated RCTs for every specific non-urological site.

Evidence in Specific Patient Groups

Research has explored the use of the gel beyond the general adult population. Specific trials was evaluated in infants and pediatric patients undergoing procedures like urethral catheterization. These studies monitored outcomes related to patient-reported outcomes describing perceived discomfort. However, results apply only to the populations studied, and dedicated comparative evidence is not always highlighted for other specific groups, such as older adults.

Durability of Effect and Follow-up in Clinical Trials

The research focuses almost entirely on short-term symptom patterns. The follow-up durations were limited and designed to capture the effect during and immediately following the medical procedure itself. Long-term effects are not fully established because the trials were not designed to observe outcomes months or years after application. The evidence is limited to what is known about acute management.

What Research Gaps and Uncertainties Exist

Several areas of uncertainty remain, including trial heterogeneity regarding gel volume and application times. Another area of uncertainty is that the findings were mixed when comparing results between male and female patients. Furthermore, data for certain groups remain insufficient for non-urological applications where sample sizes were modest. These factors mean the evidence highlights what is known—and what is still uncertain—about the gel’s use.

Common questions about Instillagel (FAQ)

Q: How quickly does the numbing effect of Instillagel start working?

According to official product information, the anaesthetic effect of the gel typically starts to work within 5 to 15 minutes after it has been applied. This period allows the numbing agent to fully activate before the medical procedure begins.

Q: How long does the numbing effect of Instillagel typically last?

The official information indicates that the numbing effect of the gel generally lasts for approximately 20 to 30 minutes. This duration relates to the acute management of discomfort during and immediately following the medical procedure.

Q: Can Instillagel cause dizziness or lightheadedness?

Official product information notes that if excessive amounts of the numbing agent are absorbed into the bloodstream, it could lead to effects on the central nervous system (CNS). These effects might be characterized by symptoms such as dizziness or lightheadedness. Drowsiness is also listed as a possible side effect.

Q: Does the numbing agent in Instillagel enter the bloodstream?

Yes, the active numbing agent, Lidocaine, is absorbed into the bloodstream after the gel is applied to mucous membranes. Regulatory documents state that blood concentrations usually remain low. However, the risk of higher systemic absorption is noted when the treated surface is already damaged or bleeding.

Q: Is it common to feel a mild stinging sensation when Instillagel is first applied?

Official patient information indicates that a slight stinging sensation may be felt in the area immediately after the gel is applied. This sensation is typically brief and often subsides quickly as the local numbing effect starts to take hold.

Q: Is it considered safe to use Instillagel while pregnant?

Regulatory guidance states that the use of the gel is restricted during the first three months of pregnancy. Its use during this time is only permitted when a healthcare professional has determined the procedure is absolutely necessary.

Q: Are there warnings about using Instillagel while breastfeeding?

Official regulatory guidance advises that breastfeeding should be suspended for a period of 12 hours after the gel has been administered. This is a precautionary measure related to the potential systemic absorption of the numbing agent.

Q: Is Instillagel a prescription-only medicine?

Instillagel is classified in some regulatory jurisdictions as a medicine that requires authorization, and it is commonly used under the direction of a healthcare professional. It is available to be prescribed for specific medical needs.

Q: Can Instillagel be used for general pain relief not related to a medical procedure?

Regulatory information restricts the gel's use to specific diagnostic or therapeutic procedures, such as catheterization, cystoscopy, or intubation. Its purpose is defined as ensuring patient comfort during these events, and it is not authorized for general, non-procedural pain relief.

Q: Are there any specific activities I should avoid immediately after using Instillagel?

Official guidance states that some patients may feel drowsy after the gel is used. If this effect occurs, patients are advised to refrain from activities that require clear attention and coordination, such as driving or operating machinery.

Q: Does Instillagel have an expiration date, and is it still safe after that date?

Yes, the product is labeled with an expiration date. Official patient information clearly states that the gel should not be used after the expiry date shown on the package has passed.

Q: Is Instillagel safe for use in children?

Instillagel is indicated for use in adults and children from 2 years of age. For children between 2 and 12 years old, regulatory documents note that the dose must be determined based on the child's body weight to comply with safety limits. Use is specifically contraindicated for children under the age of 2 years.

Q: Does the gel contain latex?

According to the product literature, the formulation of Instillagel, including the syringe, is described as being free of latex and natural rubber components.

Q: Can Instillagel be used for oral or dental procedures?

The official scope of application includes oropharyngeal sites, such as the mouth and throat, for procedures like intubation. The product label includes caution for use in this area because the numbing effect may increase the risk of difficulty with swallowing. The product is not specifically indicated for routine dental procedures.

Q: Does Instillagel interact with herbal supplements?

The official interaction profile focuses on prescription medicines that can affect the metabolism of the active ingredient, Lidocaine. Regulatory documents specifically state that interactions between the active ingredients and herbal supplements have not been established.

Q: Are there different strengths or types of Instillagel available?

Instillagel is supplied with a standard concentration of 20 mg/g Lidocaine in the gel formulation. It is available in two different package volume sizes, typically 6 ml and 11 ml syringes, designed to accommodate various procedural requirements.

Q: What is the role of the lubricating agent in Instillagel?

The gel base is a sterile, cellulose-based lubricant. Its primary role is to ensure the smooth, low-trauma insertion of medical devices into the body orifice. The lubricant also helps ensure prolonged contact time for the active anaesthetic and antiseptic components.

Q: Can the lidocaine in Instillagel affect the heart rate?

Excessive systemic absorption of the numbing agent, Lidocaine, is officially documented as potentially causing cardiovascular reactions. These reactions may be characterized by changes in heart rate or rhythm, including the occurrence of a slowed heart rate known as bradycardia.

Q: Does Instillagel contain sugar or any components harmful to diabetics?

The composition of the gel listed in the official patient information leaflet does not include sugar or sucrose. The formulation contains excipients, such as propylene glycol, but is not noted to contain sugar components.

Q: What is the evidence base for the gel's application in non-urological settings (such as rectal examinations)?

Research has explored the use of the gel in non-urological settings, such as for rectal examinations. The evidence base for these specific uses is largely supported by established clinical practice. While studies exist, regulatory documentation notes that dedicated comparative evidence for non-urological sites is modest, with some research providing mixed results regarding pain reduction compared to plain lubricant.

How to Store and Dispose of Instillagel?

Official regulatory documents define strict rules for the storage and disposal of Instillagel.

Storage & Stability Requirement	Official Regulatory Rule
Temperature Range	Do not store above 25 C (room temperature).
Prohibited Environments	Do not refrigerate or freeze.
Stability after Opening	Must be used immediately after opening the sterile blister.
Child Safety	Keep out of the sight and reach of children.
Disposal Instructions	Discard any unused product; the syringe is for single use only.

Disposal must adhere to environmental guidelines: medicines should not be thrown into household waste or poured into drains. Expired or unused Instillagel must be returned to a pharmacist or local collection point for proper pharmaceutical waste disposal.